In addition, the Inhibition of VEGF in Age-related choroidal Neovascularization (IVAN) trial demonstrated that monthly anti-VEGF treatments are associated with a higher risk and greater development of geographic atrophy (GA) [3]. Here, VEGFA is linked to atrophic macular degeneration.